Volume 75, Issue 4
  • ISSN: 0002-9637
  • E-ISSN: 1476-1645


malaria is an important cause of morbidity in Central and South America. In Colombia, this is the most prevalent malaria infection, representing 75% of the reported cases. To define the efficacy of the chloroquine and primaquine regimen to eliminate hypnozoites and prevent relapses, we conducted a random controlled clinical trial of three primaquine regimens in an open-label study. We evaluated the anti-relapse efficacy of total primaquine doses of 45, 105, and 210 mg administered at a dosage of 15 mg/day in 210 adults with infection from the northwestern region of Colombia. Cure rates for blood-stage malaria by day 28 of follow-up were 100% in all groups. Post-treatment reappearance of parasitemia during the six months of follow-up was 45%, 36.6% and 17.6%, respectively, for each group. When compared with other groups, administration of 210 mg was a significant protection factor for reappearance of parasitemia in a malaria-endemic area.


Article metrics loading...

The graphs shown below represent data from March 2017
Loading full text...

Full text loading...



  1. Suh KN, Kain KC, Keystone JS, 2004. Malaria. CMAJ 170 : 1693–1702. [Google Scholar]
  2. Mendis K, Sina BJ, Marchesini P, Carter R, 2001. The neglected burden of Plasmodium vivax malaria. Am J Trop Med Hyg 64 : 97–106. [Google Scholar]
  3. Carmona J, 2003. La malaria en Colombia, Antioquia y las zonas de Urabá y Bajo Cauca: panorama para interpretar la falla terapéutica antimalárica. Parte 1. Iatreia 16 : 299–318. [Google Scholar]
  4. Soto J, Toledo J, Gutierrez P, Luzz M, Llinas N, Cedeno N, Dunne M, Berman J, 2001. Plasmodium vivax clinically resistant to chloroquine in Colombia. Am J Trop Med Hyg 65 : 90–93. [Google Scholar]
  5. Blair S, Tobón A, Echeverri M, Alvarez G, Carmona J, 2002. Adecuada respuesta clínica y parasitológica de Plasmodium vivax a la cloroquina en Colombia (Turbo, Antioquia), 2001. Infectio 6 : 21–26. [Google Scholar]
  6. World Health Organization, 1990. Practical chemotherapy of malaria. Report of a WHO Scientific Group. World Health Organ Tech Rep Ser 805 : 1–141. [Google Scholar]
  7. Beutler E, 1997. Glucose-6-phospate dehydrogenase deficiency, diagnosis, clinical and genetic implications. Am J Clin Pathol 47 : 1967. [Google Scholar]
  8. Baird JK, Rieckmann KH, 2003. Can primaquine therapy for vivax malaria be improved? Trends Parasitol 19 : 115–120. [Google Scholar]
  9. Gogtay N, Garg M, Kadam V, Kamtekar K, Kshirsagar NA, 1998. A 5 days primaquine regimen as anti-relapse therapy for Plasmodium vivax. Trans R Soc Trop Med Hyg 92 : 341. [Google Scholar]
  10. Abdon NP, Pinto AY, das Silva Rdo S, de Souza JM, 2001. Assessment of the response to reduced treatment schemes for vivax malaria. Rev Soc Bras Med Trop 34 : 343–348. [Google Scholar]
  11. Bunnag D, Karbwang J, Thanavibul A, Chittamas S, Ratanapongse Y, Chalermrut K, Bangchang KN, Harinasuta T, 1994. High dose of primaquine in primaquine resistant vivax malaria. Trans R Soc Trop Med Hyg 88 : 218–219. [Google Scholar]
  12. Bergonzoli G, Rivers Cuadra JC, 2000. Therapeutic efficacy of different antimalarial regimens in the Costa Rica-Nicaragua border region. Rev Panam Salud Publica 7 : 366–370. [Google Scholar]
  13. Lacharme L, Carmona J, Tobon A, Blair S, 1998. Respuesta de P. vivax al esquema terapéutico cloroquina-primaquina en Zaragoza y Turbo, Colombia. Infectio 2 : 90–94. [Google Scholar]
  14. Lwanga SK, Lameshow S, 1991. Determinación del Tamaño Muestral en los Estudios Sanitarios. Manual Prático. Geneva: World Health Organization.
  15. World Health Organization, 2000. Severe falciparum malaria. Trans R Soc Trop Med Hyg 94 (Suppl 1): 1–90. [Google Scholar]
  16. Alecrim Md G, Alecrim W, Macedo V, 1999. Plasmodium vivax resistance to chloroquine (R2) and mefloquine (R3) in Brazilian Amazon region. Rev Soc Bras Med Trop 32 : 67–68. [Google Scholar]
  17. Phillips EJ, Keystone JS, Kain KC, 1996. Failure of combined chloroquine and high-dose primaquine therapy for Plasmodium vivax malaria acquired in Guyana, South America. Clin Infect Dis 23 : 1171–1173. [Google Scholar]
  18. Ruebush TK 2nd, Zegarra J, Cairo J, Andersen EM, Green M, Pillai DR, Marquino W, Huilca M, Arevalo E, Garcia C, Solary L, Kain KC, 2003. Chloroquine-resistant Plasmodium vivax malaria in Peru. Am J Trop Med Hyg 69 : 548–552. [Google Scholar]
  19. Baird JK, Hoffman SL, 2004. Primaquine therapy for malaria. Clin Infect Dis 39 : 1336–1345. [Google Scholar]
  20. Duarte EC, Pang LW, Ribeiro LC, Fontes CJ, 2001. Association of subtherapeutic dosages of a standard drug regimen with failures in preventing relapses of vivax malaria. Am J Trop Med Hyg 65 : 471–476. [Google Scholar]
  21. Schwartz E, Regev-Yochay G, Kurnik D, 2000. Short report: a consideration of primaquine dose adjustment for radical cure of Plasmodium vivax malaria. Am J Trop Med Hyg 62 : 393–395. [Google Scholar]

Data & Media loading...


  • Received : 10 Feb 2006
  • Accepted : 11 Jun 2006

Most Cited This Month

This is a required field
Please enter a valid email address
Approval was a Success
Invalid data
An Error Occurred
Approval was partially successful, following selected items could not be processed due to error